» Articles » PMID: 30430113

Role of Bile Acids in Colon Carcinogenesis

Overview
Specialty General Medicine
Date 2018 Nov 16
PMID 30430113
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Bile acids (BAs) are cholesterol derivatives synthesized in the liver and then secreted into the intestine for lipid absorption. There are numerous scientific reports describing BAs, especially secondary BAs, as strong carcinogens or promoters of colon cancers. Firstly, BAs act as strong stimulators of colorectal cancer (CRC) initiation by damaging colonic epithelial cells, and inducing reactive oxygen species production, genomic destabilization, apoptosis resistance, and cancer stem cells-like formation. Consequently, BAs promote CRC progression multiple mechanisms, including inhibiting apoptosis, enhancing cancer cell proliferation, invasion, and angiogenesis. There are diverse signals involved in the carcinogenesis mechanism of BAs, with a major role of epidermal growth factor receptor, and its down-stream signaling, involving mitogen-activated protein kinase, phosphoinositide 3-kinase/Akt, and nuclear factor kappa-light-chain-enhancer of activated B cells. BAs regulate numerous genes including the human leukocyte antigen class I gene, p53, matrix metalloprotease, urokinase plasminogen activator receptor, Cyclin D1, cyclooxygenase-2, interleukin-8, and miRNAs of CRC cells, leading to CRC promotion. These evidence suggests that targeting BAs is an efficacious strategies for CRC prevention and treatment.

Citing Articles

Gradient boosting reveals spatially diverse cholesterol gene signatures in colon cancer.

Yang X, Chatterjee D, Couetil J, Liu Z, Ardon V, Chen C Front Genet. 2024; 15:1410353.

PMID: 39678375 PMC: 11638177. DOI: 10.3389/fgene.2024.1410353.


Antioxidant Role of Probiotics in Inflammation-Induced Colorectal Cancer.

Hamamah S, Lobiuc A, Covasa M Int J Mol Sci. 2024; 25(16).

PMID: 39201713 PMC: 11354872. DOI: 10.3390/ijms25169026.


Obesity-Associated Colorectal Cancer.

Gonzalez-Gutierrez L, Motino O, Barriuso D, de la Puente-Aldea J, Alvarez-Frutos L, Kroemer G Int J Mol Sci. 2024; 25(16).

PMID: 39201522 PMC: 11354800. DOI: 10.3390/ijms25168836.


Interactions between Dietary Antioxidants, Dietary Fiber and the Gut Microbiome: Their Putative Role in Inflammation and Cancer.

Munteanu C, Schwartz B Int J Mol Sci. 2024; 25(15).

PMID: 39125822 PMC: 11311432. DOI: 10.3390/ijms25158250.


Colorectal cancer and inulin supplementation: the good, the bad, and the unhelpful.

Oliero M, Alaoui A, McCartney C, Santos M Gastroenterol Rep (Oxf). 2024; 12:goae058.

PMID: 38984069 PMC: 11231048. DOI: 10.1093/gastro/goae058.


References
1.
Alberts D, Martinez M, Hess L, Einspahr J, Green S, Bhattacharyya A . Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst. 2005; 97(11):846-53. DOI: 10.1093/jnci/dji144. View

2.
Rial N, Lazennec G, Prasad A, Krouse R, Lance P, Gerner E . Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer. Int J Cancer. 2009; 124(10):2270-80. PMC: 2669776. DOI: 10.1002/ijc.24226. View

3.
Newmark H, Wargovich M, Bruce W . Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer Inst. 1984; 72(6):1323-5. View

4.
Qiao D, Gaitonde S, Qi W, Martinez J . Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation. Carcinogenesis. 2001; 22(6):957-64. DOI: 10.1093/carcin/22.6.957. View

5.
Baek M, Park J, Park J, Kim M, Kim H, Bae W . Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. Cancer Lett. 2009; 290(1):123-8. DOI: 10.1016/j.canlet.2009.08.030. View